Skip to main content
SpringerLink
Log in

The microbiology of cefoperazone

Mikrobiologie von Cefoperazon

  • Microbiology
  • Published:
Infection Aims and scope Submit manuscript

Summary

Cefoperazone, a new semisynthetic, injectable ureidocephalosporin, shows excellent activity against a wide range of gram-positive and gram-negative bacteria. Strains ofEnterobacteriaceae andPseudomonas aeruginosa resistant to this drug (MIC ≥ 32 mg/l in agar dilution) are rarely encountered. Staphylococci,Haemophilus andNeisseria, whether betalactamase positive or not, are highly susceptible to cefoperazone. 90% of the isolates ofBacteroides fragilis and of enterococci are inhibited by 32 mg/l of the drug. The drug exhibits bactericidal activity. Activity is retained in the presence of a variety of betalactamases. However, some strains which produce TEM-betalactamase are resistant to cefoperazone.

Zusammenfassung

Cefoperazon ist ein neues halbsynthetisches, injizierbares Ureidocephalosporin; es ist gegen ein breites Spektrum von grampositiven und gramnegativen Bakterien ausgezeichnet wirksam. Stämme von Enterobakterien undPseudomonas aeruginosa mit Resistenz (MHK ≥ 32 mg/l im Agar-Dilutionstest) werden selten beobachtet. Staphylokokken,Haemophilus und Neisserien sind hochempfindlich, unabhängig davon, ob sie Beta-Laktamase-positiv sind oder nicht. 90% der Isolate vonBacteroides fragilis und Enterokokken werden bei einer Konzentration von 32 mg/l gehemmt. Cefoperazon ist bakterizid wirksam. Bei einer ganzen Reihe von Beta-Laktamasen bleibt die Aktivitat erhalten. Einige TEM-Beta-Laktamase produzierende Stämme sind jedoch gegenüber Cefoperazon resistent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literature

  1. Ericson, H. M., Sherris, J. C. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. Sect. B Suppl. 217 (1971) 1–90.

    Google Scholar 

  2. Proceedings of the First International Symposium on Cefoperazone Sodium. Boston, October 1979. Clin. Therap. 3 (1980) 1–208.

    Google Scholar 

  3. Devaud, M., Kayser, F. H. Characterization of multiresistant isolates ofAcinetobacter calcoaceticus causing nosocomial infections. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Diseases. American Society for Microbiology, Washington D. C., 1980, pp. 735–737.

    Google Scholar 

  4. Kayser, F. H. Resistenz methicillinresistenter Staphylokokken gegenüber neuen Cephalosporin-Antibiotika. Infection 8 (1980) 165–170.

    Google Scholar 

  5. Jacobus, N. V., Tally, F. P., Barza, M., Gorbach, S. L. Susceptibility of anaerobic bacteria to cefoperazone and other beta-lactam antibiotics. Clin. Therap. 3 (1980) 34–38.

    Google Scholar 

  6. Borobio, M. V., Aznar, J., Jimenez, R., Garcia, F., Perea, E. J. Comparativein vitro activity of 1-oxa-β-lactam (LY 127935) and cefoperazone with other β-lactam antibiotics against anaerobic bacteria. Antimicrob. Agents Chemother. 17 (1980) 129–131.

    Google Scholar 

  7. Neu, H. C., Fu, K. P., Aswapokee, N., Aswapokee, P., Küng, K. Comparative activity and β-lactamase stability of cefoperazone, a piperacillin cephalosporin. Antimicrob. Agents Chemother. 16 (1979) 150–157.

    Google Scholar 

  8. Hall, W. H., Opfer, B. J., Gerding, D. N. Comparative activities of the oxa-β-lactam LY 127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli. Antimicrob. Agents Chemother. 17 (1980) 273–279.

    Google Scholar 

  9. Blandino, G., Dubini, F., Russo, G., Cocuzza, G. Microbiological evaluation of cefoperazone, a new semisynthetic cephalosporin. Clin. Therap. 3 (1980) 103–111.

    Google Scholar 

  10. Wise, R., Gillett, A. P., Andrews, J. M. A study of thein vitro activity of cefoperazone: A comparison with other beta-lactam antibiotics. Clin. Therap. 3 (1980) 149–155.

    Google Scholar 

  11. Matsubara, N., Minami, S., Muraoka, T., Saikawa, I., Mitsuhashi, S. In vitro antibacterial activity of cefoperazone (T-1551), a new semisynthetic cephalosporin. Antimicrob. Agents Chemother. 16 (1980) 731–735.

    Google Scholar 

  12. Welch, D. F., Matsen, J. M. Bactericidal activity of cefoperazone in comparison with other beta-lactam antibiotics and gentamicin. Clin. Therap. 3 (1980) 127–129.

    Google Scholar 

  13. Auckenthaler, R., Waldvogel, F. A. In vitro activity of a new semisynthetic cephalosporin: Cefoperazone. Clin. Therap. 3 (1980) 89–97.

    Google Scholar 

  14. Mitsuhashi, S., Minami, S., Matsubara, N., Yotsuji, A., Kurashige, S., Saikawa, I. In vitro andin vivo activity of cefoperazone. Clin. Therap. 3 (1980) 1–13.

    Google Scholar 

  15. Mathew, M. Plasmid-mediated β-lactamases of gram-negative bacteria: Properties and distribution. J. Antimicrob. Chemother. 5 (1979) 349–358.

    Google Scholar 

  16. Nishida, M., Kamimura, T., Okado, N., Matsumoto, Y., Mine, Y., Murakawa, T. Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK749) with other cephalosporin antibiotics. J. Antibiot. 12 (1980) 1319–1327.

    Google Scholar 

  17. Schmid, B., Kayser, F. H. Resistenz gegen β-Laktam-Antibiotika und Aminoglycoside bei gramnegativen Bakterien. 1. Molekulare und genetische Charakterisierung von R-Faktoren. Zbl. Bakt. I. Abt. Orig. A 234 (1976) 371–383.

    Google Scholar 

  18. Kayser, F. H., Devaud, M., Largiadèr, F., Binswanger, U. Acquisition of multiple antibiotic resistance bySalmonella dublin from the gram-negative hospital flora, in a kidney allograft recipient. Zbl. Bakt. I Abt. Orig. A 241 (1978) 308–318.

    Google Scholar 

  19. Kayser, F. H., Homberger, F., Devaud, M. Genetic analysis of multiple-antibiotic resistance inSalmonella dublin. In:Nelson, J. D., Grassi, C. (eds.): Current Chemotherapy and Infectious Diseases. American Society for Microbiology, Washington D. C., 1980, pp. 734–735.

    Google Scholar 

  20. Odakura, Y., Tanaka, T., Hashimoto, H., Mitsuhashi, S. Mutation of R-factors capable of specifying hypersynthesis of penicillinase. Antimicrob. Agents Chemother. 3 (1973) 315–324.

    Google Scholar 

  21. Thornsberry, C., Baker, C. N., Barry, A. L., Jones, R. N. Cefoperazone: Evaluation of thein vitro activity and an analysis of the disk diffusion test. Clin. Therap. 3 (1980) 39–45.

    Google Scholar 

  22. English, A. R., Retsema, J. A., Girard, A. E., Lynch, J. E., Barth, W. E. CP-45899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: Initial bacteriological characterization. Antimicrob. Agents Chemother. 14 (1978) 414–419.

    Google Scholar 

  23. Spratt, B. G. Properties of the penicillin-binding proteins ofEscherichia coli K-12. Eur. J. Biochem. 72 (1977) 341–352.

    Google Scholar 

  24. Noguchi, H., Matsuhashi, M., Takaoka, M., Mitsuhashi, S. New antipseudomonal penicillin, PC-904: Affinity to penicillin-binding proteins and inhibition of the enzyme cross-linking peptidoglycan. Antimicrob. Agents Chemother. 14 (1978) 617–624.

    Google Scholar 

  25. Curtis, A. N., Orr, D., Ross, G. W., Boulton, M. G. Affinities of penicillins and cephalosporins for the penicillin-binding proteins ofEscherichia coli K-12 and their antibacterial activity. Antimicrob. Agents Chemother. 16 (1979) 533–539.

    Google Scholar 

  26. Kayser, F. H. Microbiological studies on cefoperazone. Clin. Therap. 3 (1980) 24–33.

    Google Scholar 

  27. Shimizu, K. Cefoperazone: Absorption, excretion, distribution, and metabolism. Clin. Therap. 3 (1980) 60–79.

    Google Scholar 

  28. Craig, W. A. Single-dose pharmacokinetics of cefoperazone following intravenous administration. Clin. Therap. 3 (1980) 46–49.

    Google Scholar 

  29. Balant, L., Dayer, P., Rudhardt, M., Allaz, A. F., Fabre, J. Cefoperazone: Pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin. Therap. 3 (1980) 50–59.

    Google Scholar 

  30. Lode, H., Kemmerich, B., Koeppe, P., Belmega, D., Jendroschek, H. Comparative pharmacokinetics of cefoperazone and cefotaxime. Clin. Therap. 3 (1980) 80–88.

    Google Scholar 

  31. Jones, R. N., Fuchs, P. C., Barry, A. L., Gavan, T. L., Gerlach, E. H., Sommers, H. M. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates. Clin. Therap. 3 (1980) 14–23.

    Google Scholar 

  32. Schmid, B., Kayser, F. H. Resistenz gegen β-Laktam-Antibiotika und Aminoglycoside bei gramnegativen Bakterien. 2. Biochemischer Mechanismus der Resistenz. Zbl. Bakt. I. Abt. Orig. A 234 (1976) 384–392.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Microbiology of the University, P. O. Box, CH-8028, Zürich, Switzerland

    F. H. Kayser, E. Huf & F. Hombergen

Authors
  1. F. H. Kayser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Huf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Hombergen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kayser, F.H., Huf, E. & Hombergen, F. The microbiology of cefoperazone. Infection 9 (Suppl 1), S6–S12 (1981). https://doi.org/10.1007/BF01641031

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01641031

Keywords

Search

Navigation